-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
WCLC News
-
Preconference Workshops Offer Diverse Educational Opportunities Across Specialties
Opening day offerings include sessions on everything from compassion fatigue and building resilience to the latest in lung cancer screening and science communication.
-
Meet Us in Barcelona: What to Expect at the World Conference on Lung Cancer
IASLC President, Dr. Paul Van Schil, unveils key events and programming highlights you can look forward to at WCLC 2025.
-
Celebrate the IASLC Foundation’s Impact
Join your colleagues in recognizing more than a decade of lung cancer research made possible by the IASLC Foundation at WCLC 2025.
-
Step it Up at WCLC 2025 in Barcelona
Track your steps, win prizes, and support the IASLC Foundation by participating in the 2025 Wellness Challenge.
-
Know Before You Go: Your Guide to Navigating Barcelona
Plan ahead for WCLC 2025 with this guide to local transportation, cultural norms, and important travel documents.
-
Spotlight on the WCLC 2025 Talent Showcase
Prepare to be amazed as members of the global lung cancer community take center stage in Barcelona.
-
Data Shows Screening Programs Can Shift Stage Distribution at Diagnosis
Dr. Mike Gieske said since implementing a multidisciplinary screening approach, his healthcare system has seen a 19% decrease in late-stage lung cancers, and they now see more early-stage than late-stage lung cancers.
-
IASLC Lectureships Honor the Work of Thoracic Oncology Trailblazers
Nine difference-makers in the field of lung cancer shared their groundbreaking work during the IASLC Lectureship Awards presentations at WCLC 2024.
-
Combining Inflammatory Pathway Modulators and Immune Cell Activators with Immunotherapy May Improve or Rescue Responsiveness
Experts, including Dr. Melina E. Marmarelis, revealed different approaches to overcoming resistance to immune checkpoint inhibitors.
-
Breakthroughs in Targeting KRAS G12C Mutations in NSCLC
Dr. Ziming Li and other panelists recently explored encouraging clinical trial data for novel therapies, including garsorasib, olomorasib, fulzerasib, and divarasib.